69
Participants
Start Date
December 31, 2011
Primary Completion Date
May 31, 2016
Study Completion Date
June 30, 2016
sipuleucel-T
Sipuleucel-T is an autologous cell product consisting of antigen presenting cells (APCs) loaded with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
abiraterone acetate
Abiraterone acetate (1000 mg po QD) was administered in combination with prednisone (5 mg po BID) for a total of 26 weeks.
NYU Clinical Cancer Center, NYU Langone Medical Center, New York
The Mount Sinai Medical Center, New York
Associated Medical Professionals of New York, PLLC, Syracuse
Associated Medical Professionals of NY, PLLC, Oneida
Georgetown University Medical Center - Lombardi Cancer Center, Washington D.C.
Mid Atlantic Urology Associates, Mid Atlantic Clinical Research, Greenbelt
Urology of Virginia, Virginia Beach
Carolina Urologic Research Center, Myrtle Beach
Urology Associates, P.C., Nashville
Indiana University, Indianapolis
GU Research Center, LLC, Omaha
The Urology Center of Colorado, Denver
Cancer Center Oncology Medical Group, La Mesa
UCSD Medical Center - La Jolla, La Jolla
Moores UCSD Cancer Center, La Jolla
UCSD Medical Center - Hillcrest, San Diego
Medical Oncology Associates - SD, San Diego
Sharp Rees-Stealy, San Diego
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Providence Cancer Center Oncology and Hematology Care, Portland
Virginia Mason Medical Center, Seattle
Lead Sponsor
Dendreon
INDUSTRY